Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies

NCT07701889 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Diseases

Interventions

BIOLOGICAL: 20-19 Tan BB06oz CAR T

Sponsor

Roswell Park Cancer Institute